Search
Pozanicline
go.drugbank.com/drugs/DB05458InvestigationalIn radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR subtypes. … ABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity
Lecithin, soybean
go.drugbank.com/drugs/DB14161InvestigationalThe emulsifying and surfactant properties are useful in food additives and for forming organogels (gels).
Mixtures: Protect Plus SO 60Hydracarbazine
go.drugbank.com/drugs/DB09243ExperimentalHydracarbazine is a pyridazine that has found use as an antihypertensive agent It was once marketed in France under the tradename Normatensyl.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeRabeximod
go.drugbank.com/drugs/DB05772InvestigationalRabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.
Artemisia vulgaris root
go.drugbank.com/drugs/DB14170ApprovedArtemisia vulgaris root allergenic extract is used in allergenic testing.
Mixtures: Toe Corrector CompositeDexloxiglumide
go.drugbank.com/drugs/DB04856InvestigationalAs the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent. … Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.
Benzododecinium
go.drugbank.com/drugs/DB13282InvestigationalIt has been marketed as a tincture for antiseptic product for wounds in the Czech Republic.
Categories: Compounds used in a research, industrial, or household settingTBC-3711
go.drugbank.com/drugs/DB05407InvestigationalTBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
VTP-201227
go.drugbank.com/drugs/DB05652ExperimentalIt is being developed by Vitae Pharmaceuticals. … VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.
MX6
go.drugbank.com/drugs/DB05789Experimental[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to … MX6 is adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer.